INVA Innoviva Inc

$20.16

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 8/22/2025

About Innoviva Inc

Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.

Website: https://www.inva.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1080014
Address
2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE, CA, US
Valuation
Market Cap
$1.15B
P/E Ratio
50.75
PEG Ratio
0.24
Price to Book
1.66
Performance
EPS
$0.36
Dividend Yield
Profit Margin
6.52%
ROE
3.43%
Technicals
50D MA
$17.77
200D MA
$18.49
52W High
$21.28
52W Low
$14.83
Fundamentals
Shares Outstanding
63M
Target Price
$19.00
Beta
0.49

INVA EPS Estimates vs Actual

Estimated
Actual

INVA News & Sentiment

Aug 14, 2025 • Benzinga NEUTRAL
Congressional Trading Report: Rep. George Whitesides Sold Over $50K In Planet Labs Stock - Planet Labs ( NYSE:PL )
Records from August 13, 2025 indicate that Representative George Whitesides of California made a sale of Planet Labs PL, valued between $50,001 and $100,000, with the transaction dated March 27, 2025 and filed in August. As of now, Planet Labs shares are trading down 1.63% at $6.63.
Aug 13, 2025 • Motley Fool NEUTRAL
Armata Posts 59 Percent Q2 Revenue Jump
Armata Pharmaceuticals ( NYSEMKT:ARMP ) , a clinical-stage biotech developing bacteriophage therapies for drug-resistant bacterial infections, released its second-quarter results on August 12, 2025. The company posted GAAP revenue of $2.2 million, beating analyst GAAP revenue estimates of $1.38 ...
Aug 11, 2025 • Benzinga SOMEWHAT-BULLISH
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - Almonty Indus ( NASDAQ:ALM ) , ARM Holdings ( NASDAQ:ARM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Mitchell S. Kapoor initiated coverage on Crescent Biopharma, Inc.
Aug 07, 2025 • Motley Fool NEUTRAL
Innoviva ( INVA ) Q2 Sales Jump 64%
Innoviva ( NASDAQ:INVA ) , a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share ( GAAP ) of $0.77 on $100.3 million in revenue.
Jul 14, 2025 • Benzinga SOMEWHAT-BULLISH
This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Innoviva ( NASDAQ:INVA ) , Cisco Systems ( NASDAQ:CSCO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Scott Berg initiated coverage on Shopify Inc.
Jun 30, 2025 • Benzinga SOMEWHAT-BULLISH
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - Iterum Therapeutics ( NASDAQ:ITRM )
DUBLIN and CHICAGO, June 30, 2025 ( GLOBE NEWSWIRE ) -- Iterum Therapeutics plc ITRM ( "Iterum" or the "Company" ) , a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of ...
Sentiment Snapshot

Average Sentiment Score:

0.292
50 articles with scored sentiment

Overall Sentiment:

Bullish

INVA Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.15 Surprise
  • Reported EPS: $0.26
  • Estimate: $0.41
  • Whisper:
  • Surprise %: -36.6%
Nov 04, 2024
Sep 30, 2024 (Pre market)
-0.24 Surprise
  • Reported EPS: $0.02
  • Estimate: $0.26
  • Whisper:
  • Surprise %: -92.3%
Jul 31, 2024
Jun 30, 2024 (Post market)
-0.79 Surprise
  • Reported EPS: $-0.55
  • Estimate: $0.24
  • Whisper:
  • Surprise %: -329.2%
May 08, 2024
Mar 31, 2024 (Post market)
0.29 Surprise
  • Reported EPS: $0.46
  • Estimate: $0.17
  • Whisper:
  • Surprise %: 170.6%
Feb 29, 2024
Dec 31, 2023 (Post market)
0.53 Surprise
  • Reported EPS: $0.76
  • Estimate: $0.23
  • Whisper:
  • Surprise %: 230.4%
Nov 01, 2023
Sep 30, 2023 (Post market)
0.71 Surprise
  • Reported EPS: $0.98
  • Estimate: $0.27
  • Whisper:
  • Surprise %: 263.0%
Aug 02, 2023
Jun 30, 2023 (Post market)
-0.24 Surprise
  • Reported EPS: $0.02
  • Estimate: $0.26
  • Whisper:
  • Surprise %: -92.3%
May 09, 2023
Mar 31, 2023 (Post market)
0.19 Surprise
  • Reported EPS: $0.42
  • Estimate: $0.23
  • Whisper:
  • Surprise %: 82.6%
Feb 28, 2023
Dec 31, 2022 (Post market)
-1.21 Surprise
  • Reported EPS: $-0.98
  • Estimate: $0.23
  • Whisper:
  • Surprise %: -526.1%

Financials